The marketing application was withdrawn before the European Medicines Agency had finished re-examining its earlier recommendation to reject the drug.
Biogen has withdrawn the EU marketing authorization application (MAA) for Aduhelm (aducanumab) after learning it was unlikely to convince the European Medicines Agency to reverse its recommendation last year that the Alzheimer’s disease drug should not be approved for use in the EU.
The withdrawal took place on 20 April but was announced today. It follows interactions with the EMA’s human medicines committee,...
<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>
As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.
<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>
A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.
With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.
